Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher, Nizar M Tannir, Lihua E Budde, Simon J Harrison, Sebastian Klobuch, Sagar S Patel, Luis Meza, Mary-Lee Dequeant, Anna Ma, Qiuling Ally He, Leah M Williams, Alissa Keegan, Ellen B Gurary, Henia Dar, Sushant Karnik, Changan Guo, Heidi Heath, Rachel R Yuen, Phuong K Morrow, Neeraj Agarwal, Samer A Srour
UNLABELLED: Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial...
April 5, 2024: Cancer Discovery